4-(三氟甲氧基)苯氧基乙酸 | 72220-50-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(三氟甲氧基)苯氧基乙酸
• 中文别名: 2-[4-(三氟甲氧基)苯氧基]乙酸；4-三氟甲氧基苯氧基乙酸
• 英文名称: 2-[4-(trifluoromethoxy)phenoxy]acetic acid
• 英文别名: (4-trifluoromethoxyphenoxy)-acetic acid；4-(trifluoromethoxy)phenoxyacetic acid；4-trifluoromethoxyphenoxyacetic acid；2-(4-(Trifluoromethoxy)phenoxy)acetic acid
• CAS: 72220-50-9
• 化学式: C₉H₇F₃O₄
• mdl: MFCD00052352
• 分子量: 236.147
• InChiKey: QHSBEEUEIRDHCD-UHFFFAOYSA-N

物化性质

• 熔点：
  84-86°C
• 沸点：
  282.2±35.0 °C(Predicted)
• 密度：
  1.431±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  远离氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2918990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	2-[4-(Trifluoromethoxy)phenoxy]acetic acid 97% Material Safety Data Sheet
Synonym:
CAS:	72220-50-9

Section 1 - Chemical Product MSDS Name:2-[4-(Trifluoromethoxy)phenoxy]acetic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
72220-50-9	2-[4-(Trifluoromethoxy)phenoxy]acetic	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 72220-50-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 91.7 - 93.6 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H7F3O4
Molecular Weight: 236

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 72220-50-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-[4-(Trifluoromethoxy)phenoxy]acetic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 72220-50-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 72220-50-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 72220-50-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(三氟甲氧基)苯氧基乙酸 在 氯化亚砜 作用下， 生成 4-(三氟甲氧基)苯氧基乙酰氯
  参考文献：
  名称：

  Treatment of mastitis

  摘要：

  该发明提供了一种新的氟化头孢菌素抗生素，其化学式为I，其中Ra、Rb、Rc、Rd和Re独立地为H、F或具有至少一个氟取代基的C1-C6烷基-(Z)n—基团；X为O或S；Y为S、O或—CH2—；Z为O、S、—SO—或—SO2—；m和n独立地为0或1；R1为H、C1-C6烷基、苯基或苄基，每种基团可选择性地具有最多三个取代基，所述取代基选自卤素、C1-C4烷氧基、苯基、NO2、C1-C6烷酰基、苯甲酰基或C1-C6烷酰氧基；或其生理上可接受的盐；以及使用这些抗生素预防、治疗或治疗感染，特别是在反刍动物中的乳腺炎的方法。

  公开号：

  US06369049B1
• 作为产物：
  描述：

  (4-trifluoromethoxyphenoxy)-acetic acid tert-butyl ester 在 三氟乙酸 作用下， 以 三氟乙酸 为溶剂， 反应 3.0h， 生成 4-(三氟甲氧基)苯氧基乙酸
  参考文献：
  名称：

  Anaplastic lymphoma kinase modulators and methods of use

  摘要：

  本发明涉及公式I的化合物，其中L、X、Y、Z、R1、R2、R3和R4在此定义。该发明还提供了使用这些化合物抑制激酶，更具体地是ALK激酶的方法。本发明提供了用于调节蛋白激酶酶活性以调节细胞活动，如增殖、分化、程序性细胞死亡、迁移和化学侵袭的化合物。本发明的化合物抑制、调节和/或调节与上述细胞活动相关的激酶受体信号转导途径，并且该发明包括含有这些化合物的组合物，以及使用它们治疗激酶依赖性疾病和病况的方法；（公式I）。

  公开号：

  US07973061B2

文献信息

• [EN] MODULATORS OF THE INTEGRATED STRESS PATHWAY<br/>[FR] MODULATEURS DE LA VOIE DE RÉPONSE INTÉGRÉE AU STRESS
  申请人：CALICO LIFE SCIENCES

  公开号：WO2017193063A1

  公开（公告）日：2017-11-09

  Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

  本文提供了用于调节综合应激反应（ISR）并治疗相关疾病、疾患和症状的化合物、组合物和方法。
• Synthesis and cytotoxicity of novel 20-<i>O</i>-linked homocamptothecin ester derivatives as potent topoisomerase I inhibitors
  作者：Di-Zao Li、Cun-Ying Wang、Rui-Hua Liu、Yan-Ming Wang、Teng-Fei Ji、Yu-Rong Li、Xian-Dao Pan

  DOI：10.1080/10286020.2013.855203

  日期：2013.11.1

  attempt to improve the antitumor activity of homocamptothecins (hCPTs), a series of novel 20-O-linked hCPT ester derivatives were first designed and synthesized based on a synthetic route, by which hCPTs are acylated with different substituted phenoxyacetic acid ester derivatives. Most of the derivatives were assayed for in vitro cytotoxicity against six human cancer cell lines KB, KB/VCR, A549, HCT-8, Bel7402

  为了改善高喜树碱（hCPT）的抗肿瘤活性，首先基于合成路线设计和合成了一系列新颖的20- O-连接的hCPT酯衍生物，通过该合成路线，hCPT被不同的取代的苯氧基乙酸酯衍生物酰化。对大多数衍生物进行了针对六种人类癌细胞系KB，KB / VCR，A549，HCT-8，Bel7402和A2780的体外细胞毒性测定，并且大多数测定的化合物对这些肿瘤细胞系表现出良好的抗增殖活性，尤其是对KB
• Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
  申请人：Taisho Pharmaceutical Co. Ltd.

  公开号：EP1464335A3

  公开（公告）日：2007-05-09

  The present invention relates to compounds of the Formula (I) wherein Q is: which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  这项发明涉及式(I)的化合物 其中Q是： 这些化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的使用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食障碍，包括暴食症、厌食症、精神障碍，包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍，包括帕金森病、癫痫和成瘾症。
• ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES
  申请人：Herman Jean

  公开号：US20140088088A1

  公开（公告）日：2014-03-27

  The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, Formulas (I), (II), (III) and (IV) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of proliferative disorders and pathologic conditions such as, but not limited to, cancer such as leukemia.

  本发明涉及式I、II、III或IV的化合物，和/或其药用可接受的加合物盐和/或其立体异构体和/或其溶剂化合物，式(I)、(II)、(III)和(IV)中R1、R2、R3、R4、R5、R6、R7、R8、R9、R11和R12如权利要求书中所定义或在发明说明书中详细描述的那样，以及使用所述化合物来治疗或预防增殖性疾病以及用于制造治疗或预防增殖性疾病的药物，特别是像白血病这样的癌症。本发明还涉及所述化合物的药物组合物以及使用所述药物组合物来治疗或预防增殖性疾病。本发明还涉及将所述化合物用作生物活性成分，更具体地用作治疗增殖性疾病和病理状况的药物，例如癌症如白血病等。
• Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists
  作者：Sanjita Sasmal、Gade Balaji、Hariprasada R. Kanna Reddy、D. Balasubrahmanyam、Gujjary Srinivas、ShivaKumar Kyasa、Pradip K. Sasmal、Ish Khanna、Rashmi Talwar、J. Suresh、Vikram P. Jadhav、Syed Muzeeb、Dhanya Shashikumar、K. Harinder Reddy、V.J. Sebastian、Thomas M. Frimurer、Øystein Rist、Lisbeth Elster、Thomas Högberg

  DOI：10.1016/j.bmcl.2012.03.050

  日期：2012.5

  mediator of energy homeostasis and plays a role in metabolic and CNS disorders. The modeling-supported design, synthesis and multi-parameter optimization (biological activity, solubility, metabolic stability, hERG) of novel quinazoline derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. Clusters of refined hMCHR1

  黑色素浓缩激素（MCH）是能量稳态的重要介质，在代谢和中枢神经系统疾病中发挥作用。描述了作为 MCHR1 拮抗剂的新型喹唑啉衍生物的模型支持设计、合成和多参数优化（生物活性、溶解度、代谢稳定性、hERG）。举例说明了该系列先导化合物减肥原理的体内证明。开发了源自​​ β2-肾上腺素能受体 X 射线结构（包括细胞外环）的精制 hMCHR1 同源模型簇，并用于指导设计。